Management

Craig joined Anthera as President & Chief Operating Officer in January 2016 and became Chief Executive Officer in November 2016.  Prior to Anthera, Craig was the Chief Operating Officer for Tetraphase Pharmaceuticals.  Prior to Tetraphase, Craig served as Chief Commercial Officer for Trius Therapeutics through the acquisition of Trius by Cubist Pharmaceuticals. Prior to Trius, Craig served in various global and U.S. commercial roles at Pfizer Inc. from 2003 to December 2010 ultimately serving as Vice President of Marketing for Pfizer’s Specialty Care Business Unit.  From 1992 to 2003, Craig served in positions of increasing responsibility at Merck & Co., Inc

Craig holds a Bachelor’s degree in Commerce from McMaster University and an M.B.A. from the University of Notre Dame.

Dr. Shanahan joined Anthera as Chief Medical Officer in August 2016.  Prior to Anthera, Dr. Shanahan served as Chief Medical Officer of Arena Pharmaceuticals from 2004 to June 2016. Prior to Arena Pharmaceuticals, he served as Tanox Inc.’s Chief Medical Officer from August 2000 until March 2004. Dr. Shanahan served as Vice President, Drug Development of Isis Pharmaceuticals (now Ionis) from 1995 to August 2000 and as Senior Director in 1994. Prior to that, he was Director of Clinical Research at Pfizer Central Research from 1990 to 1994. At Searle Research and Development, he held Associate Director and Director of Clinical Research positions from 1986 to 1989. In addition, he has held various academic positions in divisions of rheumatology, including Assistant Professor and  Clinical Associate Professor at the University of Connecticut and Adjunct Assistant Professor at Northwestern University.

Dr. Shanahan holds an A.B. degree from Dartmouth College, an M.D. degree from the University of California, San Francisco, and a J.D. degree from Loyola University, Chicago.

Dr. Olson joined Anthera in April 2010 as Vice President Protein Sciences and became Chief Technology Officer in January 2016.  Prior to Anthera, Dr.Olson held management positions at Onyx, BioMarin, Cell Genesys, Coherus Biosciences, and NGM Biopharmaceuticals.  In addition, Dr. Olson spent a significant early portion of his career as a Scientist at Genentech and Staff Scientist at Bayer.

Dr. Olson has a bachelor’s degree in biology and chemistry, a masters in chemistry, and a doctorate in biochemistry.

Klara joined Anthera as Senior Vice President, Chief Regulatory Officer in 2015. Prior to Anthera, Klara served as Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc. from October 2007 to July 2014. Prior to Hyperion Therapeutics, Klara spent three years at CoTherix, Inc and was most recently Vice President, Regulatory Affairs and Healthcare Compliance Officer from January 2004 to January 2007. Prior to CoTherix, Inc., Klara held various positions at biopharmaceutical companies Scios, Inc. and DEY Laboratories, a subsidiary of Mylan, Inc.

Klara holds a BS in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.

May joined Anthera in April 2007 as the Director of Finance, assumed the role of Corporate Controller in October 2007, became Vice President of Finance in January 2011, and is currently Senior Vice President of Finance since May 2015.  Prior to joining Anthera, May served as SEC Reporting and Technical Accounting Manager at Renovis, Inc. from October 2005 to March 2007. May has been a Certified Public Accountant since 2007 and worked at the audit and assurance practice of Ernst & Young, LLP. from 2000 to 2005, focusing primarily in the life science industry.

May holds a B.S. in business administration with a concentration in accounting from San Francisco State University.

Dr. Martin joined Anthera in March 2010 as Senior Director of Clinical and Translational Sciences, assumed the role of Vice President, Nonclinical and Translational Sciences in 2011, and is currently Senior Vice President Medical Sciences since 2016.  Prior to Anthera Dr. Martin held a 14-year research tenure at Roche Pharmaceuticals from October 1996 to March 2010. Prior to Roche, Dr. Martin held a research position at Wellcome/GlaxoWellcome Research Laboratories in the UK from May 1992 through October 1996.

Dr. Martin holds a B.A. in Natural Sciences from Cambridge University, UK and a Ph.D. in Pharmacology from King’s College University of London, UK.

Print Friendly